1. TCDCA acts as a promising biomarker for hepatic cirrhosis.
2. Study involved 267 patients with HBV-related liver disease.
3. TCDCA distinguished disease stages with good sensitivity and specificity.
4. Linked lower TCDCA levels with viral suppression in antiviral therapy.
5. Increased TCDCA correlated with established liver disease markers.
6. Reported anti-inflammatory effects, promoting IL-10.
7. Study recommended larger, multicenter trials for validation.

Source: Scientific Reports